ReviewResearch and reports in urology2014
Prostate cancer: a review of active surveillance.
Review in Research and reports in urology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Benefits and harms of prostate cancer screening - predictions of the ONCOTYROL prostate cancer outcome and policy model.BMC public health · 2017Article
- Prostate cancer in men aged less than 50 years at diagnosis.World journal of urology · 2016Article
- Oxidative stress in prostate cancer patients: A systematic review of case control studies.Prostate international · 2016Review
- The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer.Diagnostics (Basel, Switzerland) · 2016Review
- Active surveillance for prostate cancer: a narrative review of clinical guidelines.Nature reviews. Urology · 2016Review
- [Value of MRI/ultrasound fusion in primary biopsy for the diagnosis of prostate cancer].Der Urologe. Ausg. A · 2016Article
- Using Electronic Health Record Data to Identify Prostate Cancer Patients That May Qualify for Active Surveillance.EGEMS (Washington, DC) · 2016Article
- Improvement of Prostate Cancer Diagnosis by Detecting PSA Glycosylation-Specific Changes.Theranostics · 2016Article
- Responses and relationship dynamics of men and their spouses during active surveillance for prostate cancer: health literacy as an inquiry framework.BMC public health · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this paper is to review the current recommendations for active surveillance in prostate cancer from the present prospective studies. Worldwide, there are increasing numbers of men with prostate cancer. It is now accepted as standard care that a number of men with favorable-risk disease can be followed with active surveillance. In 1995, the first prospective studies were initiated to assess the feasibility of active surveillance, in which the decision to intervene was determined by prostate-specific antigen and/or histological progression. The strategy was to provide therapy individualized to the biological behavior of the cancer. Clinical trials assessing active surveillance have usually included patients younger than 70 years of age, although the guidelines have changed over time for Gleason score and prostate-specific antigen, eg, doubling time, thereby changing the indication for active treatment. The present review focuses on patient selection, prospective studies reported in the literature, and future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.